Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.62 |
| ▸ | NPC1 | O15118 | 6/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | TP53 | P04637 | 3/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | SCN4A | P35499 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.51 |
| ▸ | PI4KA | P42356 | 3/20 | 0.51 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3102178 | 0.84 | CYP3A4 (0.56) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL3099739 | 0.84 | CYP3A4 (0.56) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL30944282 | 0.83 | CYP3A4 (0.69) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL3099104 | 0.81 | CYP3A4 (0.55) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL3102102 | 0.81 | CYP3A4 (0.55) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL9722833 | 0.80 | CYP3A4 (0.65) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL3106836 | 0.79 | RAB9A (0.53) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL3651863 | 0.79 | CSNK1D (0.60) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL3109645 | 0.77 | CYP3A4 (0.53) | RAB9ANPC1SMN1; SMN2TP53MAPT | |
| SCHEMBL3107120 | 0.77 | CYP3A4 (0.53) | RAB9ANPC1SMN1; SMN2TP53MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188078-B2 | 6-aryl/heteroalkyloxy benzothiazole and benzimidazole derivatives, method for preparing same, application thereof as drugs, pharmaceutical compositions and novel use in particular as C-MET inhibitors | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| US-20100273793-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS | SANOFI-AVENTIS (FR) | 2010-10-28 | — | — | US | disclosed |
| CN-101827827-A | Derivatives of 6-aryl/heteroalkoxybenzothiazoles and benzimidazoles, method for preparing same, use thereof as medicaments, pharmaceutical compositions and novel use thereof, in particular as CMET inhibitors | SANOFI AVENTIS | 2010-09-08 | — | — | CN | disclosed |
| EP-2205568-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS | Sanofi-Aventis (FR) | 2010-07-14 | — | — | EP | disclosed |
| WO-2009087305-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS C-MET INHIBITORS | SANOFI-AVENTIS (FR) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100273793-A1 | 6-ARYL/HETEROALKYLOXY BENZOTHIAZOLE AND BENZIMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, APPLICATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS AND NOVEL USE IN PARTICULAR AS c-MET INHIBITORS | MET, ALK, JAK2 | RAB9A 2116/4885NPC1 1581/4885SMN1; SMN2 4485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.